Introduction. - Oncogenic osteomalacia (OO) is a rare paraneoplastic syndrome characterized by severe hypophosphatemia induced by phosphaturic factors which are secreted by some tumors of mesenchymal origin. Fibroblast Growth Factor 23 (FGF-23) belongs to this family. Measurement of FGF-23 might improve the diagnosis of OO. Exegesis. - We report the case of 71-year-old Caucasian man who had a history of severe osteomalacia with multiples fractures and extreme hypophosphatemia with hyperphosphaturia and normal serum calcium level. Serum FGF-23 was 199 RU/ml (N <100 RU/ml). The tumor, detected by F-18 FDG PET/CT SCAN was localized in the mandible. Surgical removal of the tumor relieved all symptoms with normalization of serum phosphate levels within 3 days after surgery. Conclusion. - We conclude that FGF-23 measurement is likely to be of considerable importance for facilitating early diagnosis of OO. © 2004 Elsevier SAS. Tous droits réservés.
Dupond, J. L., Magy, N., Mahammedi, M., Prie, D., Gil, H., Meaux-Ruault, N., & Kantelip, B. (2005). L’ostéomalacie oncogène: Rôle des phosphatonines. Intérêt du dosage du fibroblast growth factor 23 démontré chez un malade. Revue de Medecine Interne, 26(3), 238–241. https://doi.org/10.1016/j.revmed.2004.11.013